Weekender: Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

Signup | Forward Weekender Jan.​ 30,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — Lonza Up for a career move in Cell & Gene? We're looking for scientists across our network to work with some of the world's leading Cell & Gene Therapy (CGT) experts. Browse our available CGT positions here.   Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 125 million doses of Pfizer and BioNTech's vaccine for supply in Europe. Merck stops coronavirus vaccine development in surprise setback The drugmaker, one of the largest vaccine developers, won't move forward with two candidates it's been testing after disappointing data in early trials. Lilly strikes deal to acquire drug for chronic pain The experimental treatment from Asahi Kasei Pharma adds to Lilly's pipeline of drugs for pain, including a non-opioid medicine now under review at the FDA.  Sponsored Content by Kalderos Pharma trends: Mitigate risk, embrace opportunity with contract pharmacies Learn how reframing the contract pharmacy relationship can improve drug discount program compliance. Download whitepaper. FDA approves first-of-its-kind lupus drug Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year. J&J says study data on coronavirus vaccine due 'early next week' Results from the large Phase 3 trial are highly anticipated. If proven effective, J&J's shot could provide much-needed reinforcements to a constrained immunization effort. Featured Resources FROM: Lonza Lonza is hiring cell & gene therapy teams Quality Assurance / Quality Control roles Process Development roles Manufacturing, Science and Technologies (MSAT) roles From Our Library Playbook Leveraging Real-World Evidence for Regulatory Approvals Cardinal Health Playbook The CRISPR Revolution: How Gene Editing Technology Accelerated Cell and Gene Therapy Synthego View all resources Best of What We're Reading The New York Times Governments Sign Secret Vaccine Deals. Here’s What They Hide. The Wall Street Journal When Drug Development for Rare Disease Hit Setback, Parents Were Stung Bloomberg Law Biden Delays Drug Rebate Rule That GAO Says Violates Review Law Fierce Pharma Inside the FDA Form 483 that hurt BMS' liso-cel review The Washington Post Millions earmarked for public health emergencies were used to pay for unrelated projects, inspector general says Evaluate Vantage Vir becomes a biotech bubble poster child Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip